Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

600276.SS

Hold

Jiangsu Hengrui Pharmaceuticals Co.,Ltd · Healthcare · China · $45.9B · Avg Vol: $613M/d

46
StockRank
Get insider-trade alerts
Q
79
V
23
M
36
P/E (TTM)
40.3x
ROE
14.5%
D/E
0.0x
Dividend %
0.4%
Dir. Trades · 180d
None →
Buybacks · 180d
$372.6M →

COMPANY DESCRIPTION

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is China's leading developer of innovative oncology drugs, anesthetics, and contrast agents. The company's formidable competitive moat is built on its industry-leading R&D investment, a massive sales network, and a robust pipeline of proprietary biologics and small molecules. It is the premier domestic pharmaceutical giant, successfully transitioning from generics to high-margin innovative therapies on a global scale.

FINANCIAL SUMMARY (CNY)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue21.3B22.8B28.0B31.6B14.1%32.6B33.6B39.3B11.5%
EPS (CNY)0.610.681.001.1925.0%1.161.401.6919.1%
Shares6.4B6.4B6.4B6.6B+4.0%6.4B———
Debt1.4B75.2M110.2M74.2M-62.1%67.6M———
Equity37.8B40.5B45.5B61.3B17.4%————
Op CF1.3B7.6B7.4B11.2B107.1%11.5B———
Inv CF390.3M1.2B-1.9B-2.7B—————
Fin CF-318.8M-3.1B-1.6B7.8B—————
Loading 1Y...
PRICE (1Y)-12.8%
6.927.267.607.958.29Jul 17Aug 7Aug 27
SMA 50SMA 200

Close
$6.98
RSI (14)
15.8
52W High
$10.97
From 52W High
0.6%

SCORE BREAKDOWN

Quality
79
ROIC
13.7%82.4
ROE
14.5%82.0
GP/Assets
40.7%79.3
Op. Margin
31.6%92.0
FCF/Assets
9.1%83.8
Piotroski
431.8
Int. Cover
50.0x89.3
D/E Ratio
0.00x93.4
Current Ratio
9.23x85.1
Value
23
P/E (TTM)
40.3x25.6
EV/EBITDA
33.2x17.4
P/FCF
49.2x27.6
P/B
5.0x28.5
P/S
9.5x28.1
Div Yield
0.4%8.4
Momentum
36
52W High %
64%39.7
RS 6M
—N/A
SMA 50/200
0.95x46.3
EPS Rev 4W
-7.3%12.0
EPS Rev 12W
-5.2%18.6
EPS Improve
+39%49.8
Q Growth
22%58.6

FUNDAMENTALS

Market Cap
$45.9B
P/E (Forward)
28.9x
Gross Margin
86.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600276.SS are excluded.

TickerCompanyMkt CapStockRankSignal
600276.SSJiangsu Hengrui Pharmaceuticals Co.,Ltd(you)$45.9B46Hold
600196.SSShanghai Fosun Pharmaceutical (Group) Co., Ltd.$9.1B42Hold
3692.HKHansoh Pharmaceutical Group Company Limited$28.4B77Buy
688506.SSSichuan Biokin Pharmaceutical Co.,Ltd.$16.2B12Strong Sell
300558.SZBetta Pharmaceuticals Co., Ltd.$3.1B44Hold
300142.SZWalvax Biotechnology Co., Ltd.$3.4B51Hold
000661.SZChangchun High-Tech Industry (Group) Co., Ltd.$4.8B34Sell
6887.HKSunshine Lake Pharma Co., Ltd.$2.9B45Hold
002294.SZShenzhen Salubris Pharmaceuticals Co., Ltd.$5.3B30Sell
688131.SSShanghai Haoyuan Chemexpress Co., Ltd.$3.1B41Hold

Peer medians: ROE 4.5% · P/E 28.8x · Gross margin 52.6%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SS): Stock Score Summary

Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SS) has a MoatMap StockRank of 46/100 based on Quality (79/100), Value (23/100), and Momentum (36/100) factor scores. The current signal is HOLD.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is China's leading developer of innovative oncology drugs, anesthetics, and contrast agents. The company's formidable competitive moat is built on its industry-leading R&D investment, a massive sales network, and a robust pipeline of proprietary biologics and small molecules. It is the premier domestic pharmaceutical giant, successfully transitioning from generics to high-margin innovative therapies on a global scale.

Key Financial Metrics

Price$6.98
Market Cap$45.9B
P/E (TTM)40.29
P/E (Forward)28.92
Price/Book4.98
Return on Equity14.5%
Return on Invested Capital13.7%
Debt/Equity0.00x
Gross Margin86.3%
Operating Margin31.6%
Revenue Growth13.0%
Dividend Yield0.4%
Free Cash Flow$932M

Jiangsu Hengrui Pharmaceuticals Co.,Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s (600276.SS) StockRank?
MoatMap’s StockRank for Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SS) is 46/100, with a Hold signal. It is a composite of Quality (79), Value (23), and Momentum (36) factor ranks across MoatMap’s 20,000+ stock universe.
Does Jiangsu Hengrui Pharmaceuticals Co.,Ltd have an economic moat?
Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SS) has a Quality factor score of 79/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Jiangsu Hengrui Pharmaceuticals Co.,Ltd a buy, hold, or sell?
MoatMap’s current signal for Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SS) is Hold, based on a StockRank of 46/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Jiangsu Hengrui Pharmaceuticals Co.,Ltd in?
Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).
Browse all ranked stocks600276.SS deep dive reportAI ChampionsHow we score stocksSense-check another stock